Whanin and Lundbeck jointly to launch a novel anti-depressant.

Published: 2006-01-11 07:00:00

Updated: 2006-01-11 07:00:00

Whanin and Lundbeck Korea have celebrated a joint launching ceremon of Lexapro tab., a new type of anti-depressant at Cheongho Human Resource Development Institute on Jan. 3, distributing the drug in some time January.

Lexapro (Citalopram) exhibits a serotonin dual action with far rapid onse...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK